Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 9071702, 5 pages
https://doi.org/10.1155/2017/9071702
Case Report

Chronic Myeloid Leukemia with an e6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring

1Cancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, Ireland
2Department of Haematology, St. James’s Hospital, Dublin 8, Ireland
3Department of Haematology, Bon Secours Hospital, Cork, Ireland
4Department of Haematology, Cork University Hospital, Cork, Ireland

Correspondence should be addressed to Stephen E. Langabeer; ei.semajts@reebagnals

Received 10 July 2017; Revised 13 September 2017; Accepted 17 September 2017; Published 16 October 2017

Academic Editor: Sergio Storti

Copyright © 2017 Mireille Crampe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Langabeer, “Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?” Medical Oncology, vol. 30, no. 2, article no. 508, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Hochhaus, A. Reiter, H. Skladny et al., “A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia,” Blood, vol. 88, no. 6, pp. 2236–2240, 1996. View at Google Scholar · View at Scopus
  3. M. Dupont, E. Jourdan, and J. Chiesa, “Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML [1],” Leukemia, vol. 14, no. 11, pp. 2011-2012, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Schultheis, L. Wang, R. E. Clark, and J. V. Melo, “BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis [4],” Leukemia, vol. 17, no. 10, pp. 2054-2055, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Colla, G. Sammarelli, S. Voltolini, M. Crugnola, P. Sebastio, and N. Giuliani, “E6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?” Haematologica, vol. 89, no. 5, pp. 611–613, 2004. View at Google Scholar · View at Scopus
  6. K. A. Beel, J. Lemmens, H. Vranckx, J. Maertens, and P. Vandenberghe, “CML with e6a2 BCR-ABL1 transcript: An aggressive entity?” Annals of Hematology, vol. 90, no. 10, pp. 1241–1243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Hayette, I. Tigaud, X. Thomas et al., “Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: A case report [4],” Leukemia, vol. 18, no. 10, pp. 1735-1736, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M.-J. Grégoire, V. Latger-Cannard, A. Staal et al., “Identification of an acute basophilic leukaemia carrying a rare e6a2 BCR-ABL transcript,” Acta Haematologica, vol. 116, no. 3, pp. 216–218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Yao, D. Douer, L. Wang, M. E. Arcila, K. Nafa, and A. Chiu, “A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia,” Leukemia Research Reports, vol. 7, pp. 17–19, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Popovici, S. Cailleres, M. David, M. Lafage-Pochitaloff, D. Sainty, and M.-J. Mozziconacci, “E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to imatinib,” Leukemia & Lymphoma, vol. 46, no. 9, pp. 1375–1377, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Breccia, L. Cannella, D. Diverio et al., “Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib,” Leukemia Research, vol. 32, no. 1, pp. 177–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Schnittger, U. Bacher, W. Kern, T. Haferlach, B. Hertenstein, and C. Haferlach, “A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment,” Leukemia, vol. 22, no. 4, pp. 856–858, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. H. K. Vefring, F. X. E. Gruber, L. Wee et al., “Chronic myelogenous leukemia with the e6a2 bcr-abl and lacking imatinib response: Presentation of two cases,” Acta Haematologica, vol. 122, no. 1, pp. 11–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Corm, A. Renneville, E. Rad-Quesnel, N. Grardel, C. Preudhomme, and B. Quesnel, “Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: Use of dasatinib and reduced-conditioning stem-cell transplantation [10],” Leukemia, vol. 21, no. 11, pp. 2376-2377, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. E. Langabeer, M. Crampe, J. Kelly, K. Fadalla, G. Connaghan, and E. Conneally, “Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts,” Leukemia Research, vol. 34, no. 8, pp. e204–e205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Rohon, M. Divoka, L. Calabkova et al., “Identification of e6a2 BCR-ABL fusion in a philadelphia-positive CML with marked basophilia: Implications for treatment strategy,” Biomedical Papers, vol. 155, no. 2, pp. 187–190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Grossmann, A. Kohlmann, and M. Zenger, “A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases,” Leukemia, vol. 25, no. 3, pp. 557–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Schmidt, J. Rinke, V. Schäfer et al., “Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status,” Leukemia, vol. 28, no. 12, pp. 2292–2299, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Lai, J. E. Karp, and C. S. Hourigan, “Precision medicine for acute myeloid leukemia,” Expert Review of Hematology, vol. 9, no. 1, pp. 1–3, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Baccarani, M. W. Deininger, G. Rosti et al., “European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013,” Blood, vol. 122, no. 6, pp. 872–874, 2013. View at Google Scholar
  21. S. O’Brien, J. P. Radich, C. N. Abboud et al., “Chronic myelogenous leukemia, version 1.2015,” Journal of the National Comprehensive Cancer Network, vol. 12, no. 11, pp. 1590–1610, 2014. View at Google Scholar
  22. J. Gabert, E. Beillard, V. H. J. van der Velden et al., “Standardization and quality control studies of ‘real time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—A Europe Against Cancer Program,” Leukemia, vol. 17, no. 12, pp. 2318–2357, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. J. M. Van Dongen, E. A. Macintyre, J. A. Gabert et al., “Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia,” Leukemia, vol. 13, no. 12, pp. 1901–1928, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Haslam, M. A. Catherwood, E. Dobbin, A. Sproul, S. E. Langabeer, and K. I. Mills, “Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia,” Molecular Diagnosis & Therapy, vol. 20, no. 5, pp. 457–461, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Pellagatti and J. Boultwood, “The molecular pathogenesis of the myelodysplastic syndromes,” European Journal of Haematology, vol. 95, no. 1, pp. 3–15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Boultwood, J. Perry, R. Zaman et al., “High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression,” Leukemia, vol. 24, no. 6, pp. 1139–1145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Makishima, A. M. Jankowska, M. A. McDevitt et al., “CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia,” Blood, vol. 117, no. 21, pp. e198–e206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Togasaki, J. Takeda, K. Yoshida et al., “Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia,” Blood Cancer Journal, vol. 7, no. 4, p. e559, 2017. View at Publisher · View at Google Scholar
  29. M. F. Zahid, M. M. Patnaik, N. Gangat, S. K. Hashmi, and D. A. Rizzieri, “Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy,” European Journal of Haematology, vol. 97, no. 4, pp. 313–320, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Kim, M. S. Tyndel, H. J. Kim et al., “Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy,” Blood, vol. 129, no. 1, pp. 38–47, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Guglielmelli, G. Rotunno, A. Pacilli et al., “Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients,” American Journal of Hematology, vol. 91, no. 9, pp. 918–922, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. B. L. Stein, D. M. Williams, C. O'Keefe et al., “Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: Analysis of molecular genetics and clinical phenotypes,” Haematologica, vol. 96, no. 10, pp. 1462–1469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Guglielmelli, A. Pacilli, G. Rotunno et al., “Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt myelofibrosis,” Blood, vol. 129, no. 24, pp. 3227–3236, 2017. View at Publisher · View at Google Scholar
  34. A. Zagaria, L. Anelli, N. Coccaro et al., “BCR–ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR,” Virchows Archiv, vol. 467, no. 3, pp. 357–363, 2015. View at Publisher · View at Google Scholar · View at Scopus